Hermann, M; Ruschitzka, F (2009). The hypertension peril: lessons from CETP inhibitors. Current Hypertension Reports, 11(1):76-80.
Full text not available from this repository.
View at publisher
Pharmacologic inhibitors of the cholesteryl ester transfer protein (CETP) are capable of increasing HDL cholesterol by 50% to 100% in humans. Despite intriguing antiatherogenic effects of CETP inhibition in animal models of atherosclerosis, the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events trial investigators observed an excess of cardiovascular and noncardiovascular morbidity and mortality associated with the use of the CETP inhibitor torcetrapib. This review summarizes available clinical and experimental data about potential underlying mechanisms.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Cardiology|
|Dewey Decimal Classification:||610 Medicine & health|
|Deposited On:||06 Apr 2009 13:03|
|Last Modified:||05 Apr 2016 12:53|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page